A folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy

Oncotarget

Volumn 7, Issue 32, 2016, Pages 52207-52217

  Liang, Xiao ^a   Luo, Min ^a   Wei, Xia Wei ^a   Ma, Cui Cui ^a   Yang, Yu Han ^a   Shao, Bin ^a   Liu, Yan Tong ^a   Liu, Ting ^a   Ren, Jun ^a   Liu, Li ^a   He, Zhi Yao ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Colon cancer; Folate receptor ; Gene therapy; Immunotherapy; Interleukin 15

Indexed keywords

FOLATE MODIFIED PEGYLATED LIPOSOME; FOLATE RECEPTOR 1; INTERLEUKIN 15; LIPOPLEX; LIPOSOME; RECOMBINANT INTERLEUKIN 15; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; CT26 CELL LINE; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; MOUSE MODEL; NATURAL KILLER CELL; NONHUMAN; ONCOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR NODULE; TUMOR WEIGHT; ANIMAL; BAGG ALBINO MOUSE; COLON TUMOR; DRUG DELIVERY SYSTEM; GENE THERAPY; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; FOLATE RECEPTOR 1; GENETIC THERAPY; INTERLEUKIN-15; LIPOSOMES; MICE; MICE, INBRED BALB C;

EID: 84982276343     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10537     Document Type: Article

References (50)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014; 383:1490-1502.
3. Hubbard JM and Grothey A. When less is more: maintenance therapy in colorectal cancer. Lancet. 2015; 385:1808-1810.
4. Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 2015; 520:697-701.
5. Sankpal UT, Nagaraju GP, Gottipolu SR, Hurtado M, Jordan CG, Simecka JW, Shoji M, El-Rayes B, Basha R. Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition by modulating reactive oxygen species and specific transcription factors. Oncotarget. 2016; 7:3186-3200. doi: 10.18632/oncotarget.6553.
6. Zhang Y, Lin C, Liao G, Liu S, Ding J, Tang F, Wang Z, Liang X, Li B, Wei Y, Huang Q, Li X, Tang B. MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2. Oncotarget. 2015; 6:32586-32601. doi: 10.18632/oncotarget.5309.
7. Ibraheem D, Elaissari A, Fessi H. Gene therapy and DNA delivery systems. Int J Pharm. 2014; 459:70-83.
8. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR and Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541-555.
9. Naldini L. Gene therapy returns to centre stage. Nature. 2015; 526:351-360.
10. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med. 2013; 15:65-77.
11. Wirth T, Parker N, Yla-Herttuala S. History of gene therapy. Gene. 2013; 525:162-169.
12. McCarroll JA, Dwarte T, Baigude H, Dang J, Yang L, Erlich RB, Kimpton K, Teo J, Sagnella SM, Akerfeldt MC, Liu J, Phillips PA, Rana TM, et al. Therapeutic targeting of pololike kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer. Oncotarget. 2015; 6:12020-12034. doi: 10.18632/oncotarget.2664.
13. Li J, Chen L, Liu N, Li S, Hao Y, Zhang X. EGF-coated nano-dendriplexes for tumor-targeted nucleic acid delivery in vivo. Drug Deliv. 2016; 23:1718-1725.
14. Li J, Li S, Xia S, Feng J, Zhang X, Hao Y, Chen L, Zhang X. Enhanced transfection efficiency and targeted delivery of self-assembling h-R3-dendriplexes in EGFRoverexpressing tumor cells. Oncotarget. 2015; 6:26177-26191 doi: 10.18632/oncotarget.4614.
15. Atkinson PJ, Wise AK, Flynn BO, Nayagam BA, Richardson RT. Viability of long-term gene therapy in the cochlea. Sci Rep. 2014; 4:4733.
16. Werner K, Lademann F, Thepkaysone ML, Jahnke B, Aust DE, Kahlert C, Weber G, Weitz J, Grützmann R, Pilarsky C. Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy. Oncotarget. 2016, 7:3984-3992 doi: 10.18632/oncotarget.6766.
17. Luo M, Liang X, Luo S-T, Wei X-W, Liu T, Ren J, Ma C-C, Yang Y-H, Wang B-L, Liu L, Song XR, He ZY, Wei YQ. Folate-modified lipoplexes delivering the interleukin-12 gene for targeting colon cancer immunogene therapy. J Biomed Nanotechnol. 2015; 11:2011-2023.
18. Blankenstein T, Leisegang M, Uckert W, Schreiber H. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol. 2015; 33:112-119.
19. He Z-Y, Wei X-W, Luo M, Luo S-T, Yang Y, Yu Y-Y, Chen Y, Ma C-C, Liang X, Guo F-C, Ye TH, Shi HS, Shen GB, et al. Folate-linked lipoplexes for short hairpin RNA targeting Claudin-3 delivery in ovarian cancer xenografts. J Control Release. 2013; 172:679-689.
20. Zhao D-X, Li Z-J, Zhang Y, Zhang X-N, Zhao K-C, Li Y-G, Zhang M-M, Yu X-W, Liu M-Y, Li Y. Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas. Cell Immunol. 2014; 289:155-161.
21. Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero J. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res. 2013; 73:139-149.
22. Bondurant KL, Lundgreen A, Herrick JS, Kadlubar S, Wolff RK, Slattery ML. Interleukin genes and associations with colon and rectal cancer risk and overall survival. Int J Cancer. 2013; 132:905-915.
23. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, Johnson L, Alderson MR, Watson JD, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994; 264:965-968.
24. Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res. 2014; 20:2044-2050.
25. Liu RB, Engels B, Arina A, Schreiber K, Hyjek E, Schietinger A, Binder DC, Butz E, Krausz T, Rowley DA, Jabri B, Schreiber H. Densely granulated murine NK cells eradicate large solid tumors. Cancer Res. 2012; 72:1964-1974.
26. Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC, Riddell SR. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 2009; 114:2417-2426.
27. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012; 33:35-41.
28. Gillgrass A, Gill N, Babian A, Ashkar AA. The absence or overexpression of IL-15 drastically alters breast cancer metastasis via effects on NK cells, CD4 T cells, and macrophages. J Immunol. 2014; 193:6184-6191.
29. Dadi S, Chhangawala S, Whitlock BM, Franklin RA, Luo CT, Oh SA, Toure A, Pritykin Y, Huse M, Leslie CS, Li MO. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell. 2016; 164:365-377.
30. Stephenson K, Barra N, Davies E, Ashkar A, Lichty B. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther. 2012; 19:238-246.
31. C Ochoa M, Mazzolini G, Hervas-Stubbs S, F de Sanmamed M, Berraondo P, Melero I. Interleukin-15 in gene therapy of cancer. Curr Gene Ther. 2013; 13:15-30.
32. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res. 2010; 16:6019-6028.
33. Siu MK, Kong DS, Chan HY, Wong ES, Ip PP, Jiang L, Ngan HY, Le X-F, Cheung AN. Paradoxical impact of two folate receptors, FRa and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One. 2012; 7:e47201.
34. Tiernan J, Perry S, Verghese E, West N, Yeluri S, Jayne D, Hughes T. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer. 2013; 108:662-667.
35. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009; 13:256-262.
36. Chen Y-L, Chang M-C, Huang C-Y, Chiang Y-C, Lin H-W, Chen C-A, Hsieh C-Y, Cheng W-F. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012; 6:360-369.
37. Zhang L, Zhu W, Yang C, Guo H, Yu A, Ji J, Gao Y, Sun M, Zhai G. A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting. Int J Nanomedicine. 2012; 7:151-162.
38. He ZY, Deng F, Wei XW, Ma CC, Luo M, Zhang P, Sang YX, Liang X, Liu L, Qin HX, Shen YL, Liu T, Liu YT, et al. Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex. Sci Rep. 2016; 6:23764.
39. Perrie Y, Gregoriadis G. Liposome-entrapped plasmid DNA: characterisation studies. Biochim Biophys Acta. 2000; 1475:125-132.
40. Wei X, Shao B, He Z, Ye T, Luo M, Sang Y, Liang X, Wang W, Luo S, Yang S, Zhang S, Gong C, Gou M, et al. Cationic nanocarriers induce cell necrosis through impairment of Na+/K+-ATPase and cause subsequent inflammatory response. Cell Res. 2015; 25:237-253.
41. Yoon SR, Kim T-D, Choi I. Understanding of molecular mechanisms in natural killer cell therapy. Exp Mol Med. 2015; 47:e141.
42. Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev. 2014; 260:221-234.
43. He Z, Yu Y, Zhang Y, Yan Y, Zheng Y, He J, Xie Y, He G, Wei Y, Song X. Gene delivery with active targeting to ovarian cancer cells mediated by folate receptor a. J Biomed Nanotechnol. 2013; 9:833-844.
44. He Z-Y, Chu B-Y, Wei X-W, Li J, Edwards CK, Song X-R, He G, Xie Y-M, Wei Y-Q, Qian Z-Y. Recent development of poly (ethylene glycol)-cholesterol conjugates as drug delivery systems. Int J Pharm. 2014; 469:168-178.
45. Zhou X, Li X, Gou M, Qiu J, Li J, Yu C, Zhang Y, Zhang N, Teng X, Chen Z, Luo C, Wang Z, Liu X, et al. Antitumoral efficacy by systemic delivery of heparin conjugated polyethylenimine-plasmid interleukin-15 complexes in murine models of lung metastasis. Cancer Sci. 2011; 102:1403-1409.
46. He ZY, Zheng X, Wu XH, Song XR, He G, Wu WF, Yu S, Mao SJ, Wei YQ. Development of glycyrrhetinic acidmodified stealth cationic liposomes for gene delivery. Int J Pharm. 2010; 397:147-154.
47. Ma C-C, He Z-Y, Xia S, Ren K, Hui L-W, Qin H-X, Tang M-H, Zeng J, Song X-R. α, ω-cholesterol-functionalized low molecular weight polyethylene glycol as a novel modifier of cationic liposomes for gene delivery. Int J Mol Sci. 2014; 15:20339-20354.
48. Song XR, Zheng Y, He G, Yang L, Luo YF, He ZY, Li SZ, Li JM, Yu S, Luo X, Hou SX, Wei YQ. Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. J Pharm Sci. 2010; 99:4874-4879.
49. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004; 294:15-22.
50. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2009; 254:149-154.